Related Experiment Video
Updated: Jan 30, 2026
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
[Effect of Shenmai Injection on Vascular Endothelial Dependence Diastolic Function in Coronary Heart Disease
Insights
Shenmai Injection (SI) improved vascular endothelial function in coronary heart disease (CHD) patients by increasing nitric oxide (NO) and prostacyclin (6-keto-PGF1α) levels. This treatment also boosted superoxide dismutase (SOD) activity while reducing endothelin (ET) and thromboxane B₂ (TXB₂).
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Biochemistry
Background:
- Coronary heart disease (CHD) is associated with impaired vascular endothelial function.
- Endothelial dysfunction involves imbalances in vasodilators like nitric oxide (NO) and vasoconstrictors such as endothelin (ET).
- Shenmai Injection (SI) is a traditional Chinese medicine used for cardiovascular conditions.
Purpose of the Study:
- To evaluate the effect of Shenmai Injection (SI) on vascular endothelial dependent diastolic function in patients with coronary heart disease (CHD).
- To investigate the impact of SI on key biochemical markers related to endothelial function and oxidative stress.
Main Methods:
- A randomized controlled trial involving 100 CHD patients divided into SI and control groups.
- Patients received conventional CHD treatment; the SI group additionally received intravenous SI for 10 days.
- Vascular endothelial function was assessed by measuring brachial artery diameter changes during hyperemia and after sublingual nitroglycerin.
- Serum and plasma levels of NO, endothelin (ET), thromboxane B₂ (TXB₂), 6-keto-PGF1α, and superoxide dismutase (SOD) were quantified.
Main Results:
- CHD patients exhibited significantly reduced brachial artery dilation compared to non-CHD controls.
- CHD patients showed lower NO and 6-keto-PGF1α levels, and elevated ET and TXB₂ levels.
- Compared to the control group, SI treatment significantly improved brachial artery congestion, increased NO, 6-keto-PGF1α, and SOD levels, and decreased ET and TXB₂ levels.
Conclusions:
- Shenmai Injection (SI) effectively improves vascular endothelial dependent vasodilation in CHD patients.
- SI treatment positively modulates key markers of endothelial function, including up-regulating NO and 6-keto-PGF1α.
- SI enhances antioxidant capacity by increasing SOD activity and reduces detrimental vasoconstrictors like ET and TXB₂.
Abstract:
Objective To observe the effect of Shenmai Injection (SI) on vascular endothelial dependent diastolic function in coronary heart disease (CHD) patients. Methods Totally 100 recruited CHD patients were assigned to the SI group and the control group by random digit table, 50 in each group. All patients received conventional drugs for CHD, 50 in each group. Patients in the SI group were intrave- nously injected with SI, 50 mL each time, once per day for 10 days. Changes of brachial artery diameter at hyperemia and sublingual nitroglycerin were measured in all patients before treatment and at day 10 after treatment by intravascular ultrasound. Serum NO level, plasma levels of endothelin (ET) , thromboxane B₂ (TXB₂), 6-keto-PGF₁α , superoxide dismutase (SOD) were measured using biochemical assay and ELISA. Thirty non-CHD patients confirmed with coronary CT or coronary angiogram were recruited as the non-CHD group. Results Changed value of brachial artery diameter at hyperemia and after sublingual nitroglycerin were more obviously reduced in the CHD group than in the non-CHD group (P <0. 05, P <0. 01). Besides, levels of NO, 6-keto-PGF1α were lowered, levels of ET and TXB₂ were elevated (P < 0. 01). Compared with the control group, congestion of brachial artery was significantly improved, levels of NO and 6-keto-PGF₁α increased, SOD concentration was obviously elevated, plasma levels of ET and TXB₂ decreased in the SI group (all P <0. 05). Conclusion SI could directly up-regulate levels of NO and 6-keto-PGF₁α , increase SOD activity, decrease levels of ET and TXB₂ , and improve vascular endothelial dependent vasodilation.
Related Concept Videos
01:30Coronary Artery Disease I: Introduction
01:26Coronary Artery Disease II: Pathophysiology
01:27Coronary Artery Disease V: Interprofessional Care
01:23Rheumatic Heart Disease I: Introduction
01:30Coronary Artery Disease III: Clinical Manifestations
01:26Coronary Artery Disease IV: Preventive Measures